Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection | MicrobiomeTrials← Back to trialsNCT05242159
Prevalence and Clinical Significance of Anti-annexin A2 Antibodies in COVID-19 Infection
RecruitingOBSERVATIONAL
Trial Details
Start: 2021-05-28Est. Completion: 2026-06
Enrollment target: 300 participants Locations- CHU Amiens, Amiens, France
Other microbiome trials you might be interested in
Cardiac Amyloidosis
Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is infiltrated by the abnormal build-u…
London, United KingdomEst. completion Dec 2027
COVID-19 Infection
This is a Phase 3, randomized, actively controlled, double-blinded, double-dummy, superiority study to evaluate the effi…
Canoga Park, United StatesEst. completion Sep 27, 2027
This is a trial in which 350 primary lung transplant recipients will be randomized (1:1) to receive either Tocilizumab (…
Phoenix, United StatesEst. completion Jan 8, 2029